Dr. Dmitrij Hristodorov

Dr. Dmitrij Hristodorov is a General Partner at Forbion since March 2020, where progression included roles as Partner, Principal, and Senior Associate. Currently, Dr. Hristodorov also serves as a Board Member for multiple companies, including Beacon Therapeutics, Progentos Therapeutics, Kynexis, Rampart Bioscience, AAVantgarde Bio, Seamless Therapeutics, Complement Therapeutics, and ARMGO Pharma, with initiatives focused on gene editing and innovative treatments for various diseases. Academic credentials include a PhD in Biotechnology and Immunology, a Master's degree in Biotechnology, and a Bachelor's degree in Biotechnology, all obtained from RWTH Aachen University. Abitur education was completed at Gymnasium Zitadelle Jülich.